{"id":605686,"date":"2024-06-04T09:47:34","date_gmt":"2024-06-04T13:47:34","guid":{"rendered":"https:\/\/platohealth.ai\/ohios-finest-eight-biotech-companies-leading-the-way\/"},"modified":"2024-06-04T18:00:23","modified_gmt":"2024-06-04T22:00:23","slug":"ohios-finest-eight-biotech-companies-leading-the-way","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/ohios-finest-eight-biotech-companies-leading-the-way\/","title":{"rendered":"Ohio\u2019s finest: Eight biotech companies leading the way","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
<\/div>\n
\n

Ohio has become an <\/strong>important hub<\/strong><\/a> for the biotech industry, thanks to a mix of strong educational institutions, a strategic location, and a supportive business environment. In June 2023, CBRE released the <\/strong>U.S. Life Sciences Research Talent Report 2023<\/strong><\/a> and two cities in Ohio came out as top emerging hubs for research: Columbus with $306 million in NIH (National Institute of Health) funding and Cincinnati with $262 million. The state is home to a wide variety of biotech companies and research organizations, and this article focuses on the biotechs to know in Ohio.<\/strong><\/p>\n

\n
\n

Table of contents<\/h3>\n
    <\/ol>\n<\/div>\n<\/div>\n

    Basking Biosciences<\/strong><\/h2>\n

    Basking Biosciences, based in Columbus, Ohio, is a biotech company focused on developing therapies for acute ischemic stroke. The company aims to provide rapid and effective treatment options that can reduce the damage caused by strokes and improve patient outcomes. <\/p>\n

    Basking Biosciences works on a reversible thrombolytic therapy for acute ischemic stroke. Traditional thrombolytic therapies are designed to dissolve blood clots that obstruct blood flow to the brain. However, these treatments carry significant risks, including bleeding complications. <\/p>\n

    The company\u2019s lead product, BB-031, is a reversible thrombolytic agent, for which phase 2 clinical trials will start soon<\/a>. This agent works by targeting Von Willenbrand factor (vWF) rather than fibrin. VWF plays a critical role in hemostasis, which is the process that stops bleeding at the site of a vascular injury. The unique aspect of this therapy is its reversibility, which allows clinicians to stop the drug\u2019s activity if adverse effects, such as bleeding, occur. This approach aims to enhance the safety and effectiveness of stroke treatment.<\/p>\n

    Basking Biosciences recently raised<\/a> $55 million to support the clinical development of their thrombolytic agent. <\/p>\n

    Clarametyx Biosciences<\/strong><\/h2>\n

    Clarametyx Biosciences is a biotech company based in Columbus, Ohio, focused on developing therapies for infectious diseases. Founded to address the challenges posed by bacterial biofilms, Clarametyx aims to enhance the efficacy of existing antibiotics and develop new treatments that can effectively target and eliminate persistent bacterial infections.<\/p>\n

    Biofilms are protective layers that bacteria form to shield themselves from antibiotics, making infections difficult to treat. Clarametyx\u2019s proprietary technology targets these biofilms, breaking them down to expose the bacteria to antibiotics, thereby improving the treatment outcomes.<\/p>\n

    Clarametyx\u2019s pipeline includes several therapies designed to work in conjunction with traditional antibiotics, providing a multi-faceted approach to bacterial infections:<\/p>\n